In8bio INAB 深 滬
等待開盤 09-05 09:30:00 美东时间
2.15
-0.065
-2.93%
華盛通- 最 高2.21
- 今 開2.21
- 成交量 2.25万股
- 最 低 2.141
- 昨 收 2.215
- 總市值 976.04万
- 52周最高 16.698
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.98
- 委 比 -52.09%
- 總股本 453.97万
- 歷史最高 309.57
- 量 比 0.76
- 振 幅 3.12%
- 歷史最低 2.141
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27.06 percent. This is a 78.25 percent increase over losses of $(5.70) per share from the same
08-08 04:08
IN8bio Regains Nasdaq Compliance with Bid Price Rule
An update from IN8bio ( ($INAB) ) is now available. On June 24, 2025, IN8bio, I...
07-01 02:48
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio announced that Patient 009 with grade 4 IDH-mutant glioma treated with INB-200 gamma-delta T cell therapy has achieved 4 years progression-free survival. This outcome surpasses typical results for IDH-mutant glioma patients and highlights the potential of gamma-delta T cell therapy for treating aggressive cancers. INB-200 demonstrated extended mPFS of 16.1 months in Phase 1 trial, exceeding the standard-of-care Stupp protocol's 6.9 months....
06-09 11:00
IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.INB-200 is
06-02 19:32
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio announced new data from its Phase 1 trial of INB-200 for newly diagnosed glioblastoma multiforme (GBM). The treatment showed a median progression-free survival (mPFS) of 16.1 months, more than doubling the historical 6.9 months under the standard-of-care Stupp protocol. Four patients remained alive and progression-free for over two years, with no serious toxicities beyond typical chemotherapy side effects. The improved mPFS surpasses the h...
06-02 11:30
IN8bio Wins ISCT Abstract Award For Analytical Characterization Of Its Gamma-Delta T Cell Therapies In INB-100 AML Trial, Demonstrating Durable Relapse-Free Survival And Showcasing Consistent, Potent Anti-Cancer Activity Through Its Proprietary DeltEx Allo Manufacturing Platform
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML
05-12 20:09
快讯 | In8bio发布2025年第一季度财务报告及近期业务亮点
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlig...
05-08 04:00
美股大行评级 | Tigress Financial：维持爱彼迎"买入"评级，目标价从195美元升至200美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107588488073326592.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持ProQR Therapeutics(PRQR)"买入"评级，目标价从10美元升至12美元</p> <p>• Oppenheimer：上调内克塔治疗(NKTR)评级至"跑
03-17 10:10
IN8bio Reports Progress in Cancer Therapies
In8bio, Inc. ( ($INAB) ) has released its Q4 earnings. Here is a breakdown of t...
03-14 12:14
